Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992103 | 0.88 | KMT2A (0.46) | GRM5KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL3769514 | 0.86 | GRM5 (0.36) | GRM5KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL990983 | 0.86 | GRM5 (0.42) | GRM5NPC1RAB9A | |
| SCHEMBL3714070 | 0.84 | GRM5 (0.31) | GRM5 | |
| SCHEMBL990840 | 0.78 | GRM5 (0.60) | GRM5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL990817 | 0.78 | GRM5 (0.60) | GRM5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL990125 | 0.77 | GRM5 (0.57) | GRM5NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3284072 | 0.77 | GRM5 (0.57) | GRM5NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL992719 | 0.77 | GRM5 (0.47) | GRM5NPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL3373542 | 0.76 | GRM5 (0.42) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130052644-A1 | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) | NOVARTIS AG (CH) | 2013-02-28 | — | — | US | disclosed |
| EP-2211859-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010000763-A2 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2010-01-07 | — | — | WO | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009047296-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OP PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047303-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |